Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

TORONTO, January 5 /PRNewswire/ --

President of cbm, Prof. Allen Foster announces that cbm has expanded its areas of work to include all persons with disability, not just persons with visual loss.

For the past 100 years, cbm previously known as Christoffel Blinden Mission, and Christian Blind Mission, has worked to prevent and treat blindness and provide education and rehabilitation services for persons with visual loss.

"The organization has decided that its purpose and work is to improve the quality of life of all persons with disability, which includes those with hearing or physical impairment and mental ill health as well as those with visual loss," says Prof. Foster.

LAS VEGAS, January 4 /PRNewswire/ --

Vanguard Integrity Professionals CEO, CTO and founder, Ronn Bailey, expressed his "devastation" and "significant disappointment" in light of today's announcement that, for the first time in 30 years, the Dakar race has been cancelled. The decision to call off the race was due to direct security threats made by Al Qaeda to attack the race from Portugal to Senegal.

WASHINGTON, January 4 /PRNewswire/ --

The following is a statement of Matthew L. Myers, President, Campaign for Tobacco-Free Kids:

It is great news for global health that 2008 has started with accelerated efforts around the world to enact strong smoke-free air laws that protect all workers and the public from the serious health hazards of secondhand smoke. Already in 2008, Turkey's parliament has passed a strong smoke-free law that will apply to enclosed public places, including restaurants, bars and teahouses; France has fully implemented its smoke-free law to include bars and cafes; and eight more German states have implemented smoke-free laws.

Helius to Enhance Hughes' Business IPTV and Managed Network Service Offerings

Hughes Communications, Inc. (HUGHES), the global leader in broadband satellite network solutions and a leading broadband managed network services provider, announced today that it has entered into a definitive agreement to acquire Helius, Inc., a portfolio company of Canopy Ventures.

The acquisition is expected to be completed on or about February 4, 2008.

Upon completion of the acquisition, Helius will become a wholly owned subsidiary of Hughes and will operate closely with Hughes' North America and International enterprise businesses.

CALGARY, Canada, January 4 /PRNewswire/ -- Tristone Capital is pleased to announce the initiation of equity research coverage on Schlumberger (SLB), Halliburton (HAL), and Baker Hughes (BHI). Coverage will be led by Waqar Syed, Vice President & Director, Institutional Research, based in Tristone's Denver office. Mr. Syed began his 20 year career in the oil and gas industry as a wireline engineer with Schlumberger in the Middle East and has worked as an energy research analyst for 14 years. Mr. Syed was ranked as the No. 1 earnings forecaster in the energy sector by StarMine in 2007 and was the No. 4 overall earnings forecaster among all research analysts across all sectors.

COPENHAGEN, January 4 /PRNewswire/ --

- Summary: Genmab Has Announced a New Pre-clinical Antibody Program Called HuMax-CD32b.

Genmab A/S (OMX: GEN) announced today a new pre-clinical antibody program called HuMax-CD32b(TM). This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors. HuMax-CD32b may have therapeutic potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.